05 January 2017 – PLC wants to congratulate Neurelis on their recent US FDA Fast Track Designation for NRL-1. PLC has worked with Neurelis on the clinical and regulatory pathway of NRL-1 from its early stages and looks forward to supporting Neurelis with continued development of their intranasal diazepam spray for seizure rescue.
NEURELIS RECIEVES FDA FAST TRACK DESIGNATION FOR NRL-1
